Phone Line Dropped Calls

SIU Medicine's primary phone line, 217-545-8000, is experiencing intermittent dropped calls. We apologize for this inconvenience and are working to correct this issue as soon as possible.

News

SIU Med School Is Exclusive Site for Bladder Cancer Clinical Trial

Published Date:

Combined Drug Therapies May Prevent Need for Surgery

A new clinical trial for bladder cancer has opened exclusively at Southern Illinois University School of Medicine in Springfield. The trial will combine the current use of drug therapy placed inside the bladder with a new, intravenous drug that increases the response of the immune system. The study will determine if the combination of the two drugs is safe and potentially be more effective at eliminating the cancer cells. The new drug, pembrolizumab, may fight the disease and prevent the need for surgery.

Dr. Shaheen Alanee, assistant professor at Southern Illinois University School of Medicine, head of urologic oncology and a member of Simmons Cancer Institute (SCI) at SIU, said the trial is for aggressive, high-risk superficial bladder cancer that has not invaded the muscle of the wall of the bladder. Patients eligible for the clinical trial continue to have the disease despite previous treatment. “These patients have limited options for therapy other than surgery,”Alanee said. “No good medical therapy exists for patients who fail initial treatment, and that is what made us think of this regimen.”

Fifteen to twenty patients will be enrolled in the trial. Study participants will be treated with pembrolizumab before other treatments begin. Pembrolizumab will continue for six weeks during the course of traditional treatment and stopped several weeks after the BCG regimen is finished.

Patients will receive treatment over the course of four months. Study follow up will monitor progression of the disease or for two years following completion of the treatment, whichever occurs first.

About 50,000 cases of bladder cancer are diagnosed in the United States every year. Presently, if a patient has a recurrence of bladder cancer, the options for therapy are very limited besides surgery. The surgery entails removing the bladder and connecting the kidneys to the outside using a segment of the small bowel. “If the trial is successful, patients could be spared a major surgery with a very high risk of complications.”

The mission of Simmons Cancer Institute at SIU is to serve the people of central and southern Illinois by addressing their present and future cancer needs through education, research, patient care and community service. For more information about this and other cancer related trials at Simmons Cancer Institute call 217-545-1946 or visit www.siumed.edu/cancer.

More from SIU News

IAPA conference table

IAPA conference highlights SIU physician assistants achievements

The Illinois Academy of Physician Assistants (IAPA) hosted its Fall CME conference in Rosemont in October, its first since 2019. The group welcomed Physician Assistants, providing a platform for networking, honing skills and expertise in patient care and fostering a spirit of camaraderie.
Harbinger bust

Distinguished Alumni 2024

A trio of SIU School of Medicine alumni are being honored for their distinguished service and career accomplishments. They will be recognized at the 2024 Commencement Ceremony in May.
Dawn Defraites & Stcy Grundy

Kenniebrew, McNeese awards celebrate champions of equity, inclusion

During the 2024 Alonzo Kenniebrew Lecture on February 8, Dr. Wendi El-Amin presented awards to honor individuals and a group who continue the challenging work Dr. Kenniebrew modeled, promoting inclusive excellence and equitable practices.